Premium
COVID‐19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine
Author(s) -
Fontana Francesco,
Alfano Gaetano,
Mori Giacomo,
Amurri Alessio,
Tei Lorenzo,
Ballestri Marco,
Leonelli Marco,
Facchini Francesca,
Damiano Francesca,
Magistroni Riccardo,
Cappelli Gianni
Publication year - 2020
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15935
Subject(s) - tocilizumab , medicine , hydroxychloroquine , pneumonia , immunosuppression , covid-19 , coronavirus , viral pneumonia , intensive care medicine , kidney transplantation , transplantation , infectious disease (medical specialty) , disease
Coronavirus disease 2019 (COVID‐19) pneumonia has been poorly reported in solid organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61‐year‐old kidney transplant recipient with several comorbidities who was hospitalized and later received a diagnosis of COVID‐19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, transplant clinicians should be readily informed about new cases of COVID‐19 pneumonia in solid organ transplant recipients, with focus on therapeutic strategies employed and their outcome.